Total Funding
42
Total FundingSeries C raised
Growth Score
pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
58865
Exosome Diagnostics develops and commercializes blood-based cancer molecular diagnostics for patient stratification and disease monitoring.
William J. Kelly: Chief Financial OfficerPast Role: Repligen, CFO
Shelly Hirshon: Co-FounderPast Role: Proskauer Rose, Partner
About the Company
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology
makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.
